Pertuzumab is primarily used in the treatment of HER2-positive breast cancer. It is approved for use in combination with trastuzumab and docetaxel in patients with metastatic breast cancer. It is also used in the neoadjuvant setting (before surgery) for early-stage, HER2-positive breast cancer to shrink tumors.
